WO2008141385A1 - Inhibiteurs de polymérases virales - Google Patents
Inhibiteurs de polymérases virales Download PDFInfo
- Publication number
- WO2008141385A1 WO2008141385A1 PCT/AU2008/000714 AU2008000714W WO2008141385A1 WO 2008141385 A1 WO2008141385 A1 WO 2008141385A1 AU 2008000714 W AU2008000714 W AU 2008000714W WO 2008141385 A1 WO2008141385 A1 WO 2008141385A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- alkyl
- group
- compound
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 15
- 230000003612 virological effect Effects 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 83
- 241000710781 Flaviviridae Species 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 180
- 125000000623 heterocyclic group Chemical group 0.000 claims description 98
- -1 cyano, nitro, amino Chemical group 0.000 claims description 60
- 125000003107 substituted aryl group Chemical group 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 24
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 208000005176 Hepatitis C Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 238000006352 cycloaddition reaction Methods 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 abstract description 42
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 50
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 150000001408 amides Chemical class 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 10
- 150000002825 nitriles Chemical class 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 0 *N(C1=C2****1)N(*)C2=* Chemical compound *N(C1=C2****1)N(*)C2=* 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- MIDBCPHWRKNLBF-UHFFFAOYSA-N 1-cyclohexyl-3-oxo-2-phenylindazole-5-carboxylic acid Chemical compound C=1C=CC=CC=1N1C(=O)C2=CC(C(=O)O)=CC=C2N1C1CCCCC1 MIDBCPHWRKNLBF-UHFFFAOYSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 241000711557 Hepacivirus Species 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 150000002466 imines Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- KQBDLOVXZHOAJI-UHFFFAOYSA-N (4-phenylmethoxyphenyl)azanium;chloride Chemical compound Cl.C1=CC(N)=CC=C1OCC1=CC=CC=C1 KQBDLOVXZHOAJI-UHFFFAOYSA-N 0.000 description 3
- JIBFWXYFXWPTQF-UHFFFAOYSA-N 2-(cyclohexylamino)-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NC1CCCCC1 JIBFWXYFXWPTQF-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 3
- GYXOTADLHQJPIP-UHFFFAOYSA-N 5-bromo-2-oxo-1h-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CNC1=O GYXOTADLHQJPIP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000005698 Diels-Alder reaction Methods 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241001529916 Hepatitis GB virus B Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 241000710778 Pestivirus Species 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 2
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005251 aryl acyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000003106 haloaryl group Chemical group 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AUMKHIWGYRNOMF-MHZLTWQESA-N (2s)-2-[(1-cyclohexyl-3-oxo-2-phenylindazole-5-carbonyl)amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(C=C1C(=O)N2C=3C=CC=CC=3)=CC=C1N2C1CCCCC1 AUMKHIWGYRNOMF-MHZLTWQESA-N 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical class FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- NPLUZFFEBOIYBB-UHFFFAOYSA-N 1-(1-cyclohexyl-3-oxo-2-pyridin-2-ylindazol-5-yl)-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(N(C2CCCCC2)N(C=2N=CC=CC=2)C2=O)C2=C1 NPLUZFFEBOIYBB-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- OBHHGLQJNCLAKW-UHFFFAOYSA-N 1-cyclohexyl-3-methyl-5-oxo-2-phenylpyrazole-4-carbaldehyde Chemical compound C=1C=CC=CC=1N1C(C)=C(C=O)C(=O)N1C1CCCCC1 OBHHGLQJNCLAKW-UHFFFAOYSA-N 0.000 description 1
- WMZCRERIZXKPSV-UHFFFAOYSA-N 1-cyclohexyl-3-oxo-2-phenylindazole-6-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C(N2C=3C=CC=CC=3)=O)C=1N2C1CCCCC1 WMZCRERIZXKPSV-UHFFFAOYSA-N 0.000 description 1
- IEYLKSPHSCWCDT-UHFFFAOYSA-N 1-cyclohexyl-5-methyl-2-phenylpyrazol-3-one Chemical compound C1CCCCC1N1C(C)=CC(=O)N1C1=CC=CC=C1 IEYLKSPHSCWCDT-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GCTFDMFLLBCLPF-UHFFFAOYSA-N 2,5-dichloropyridine Chemical compound ClC1=CC=C(Cl)N=C1 GCTFDMFLLBCLPF-UHFFFAOYSA-N 0.000 description 1
- GFOVTTQVBDEYPP-UHFFFAOYSA-N 2,5-dichloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NC=C1Cl GFOVTTQVBDEYPP-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- UEYQJQVBUVAELZ-UHFFFAOYSA-N 2-Hydroxynicotinic acid Chemical compound OC(=O)C1=CC=CN=C1O UEYQJQVBUVAELZ-UHFFFAOYSA-N 0.000 description 1
- BNNICQAVXPXQAH-UHFFFAOYSA-N 2-amino-4-bromobenzoic acid Chemical compound NC1=CC(Br)=CC=C1C(O)=O BNNICQAVXPXQAH-UHFFFAOYSA-N 0.000 description 1
- CUKXRHLWPSBCTI-UHFFFAOYSA-N 2-amino-5-bromobenzoic acid Chemical compound NC1=CC=C(Br)C=C1C(O)=O CUKXRHLWPSBCTI-UHFFFAOYSA-N 0.000 description 1
- NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- CDUUKBXTEOFITR-BYPYZUCNSA-N 2-methyl-L-serine Chemical compound OC[C@@]([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-BYPYZUCNSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- QUEKGYQTRJVEQC-UHFFFAOYSA-N 2516-96-3 Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1Cl QUEKGYQTRJVEQC-UHFFFAOYSA-N 0.000 description 1
- QIFLGVGHQCGFMZ-UHFFFAOYSA-N 3-(1-cyclohexyl-3-oxo-2-pyridin-2-ylindazol-5-yl)-1h-quinazoline-2,4-dione Chemical compound C1CCCCC1N1C2=CC=C(N3C(C4=CC=CC=C4NC3=O)=O)C=C2C(=O)N1C1=CC=CC=N1 QIFLGVGHQCGFMZ-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- QUERHUCQADQNIP-UHFFFAOYSA-N 3-oxo-1,2-diphenylindazole-5-carboxylic acid Chemical compound C=1C=CC=CC=1N1C(=O)C2=CC(C(=O)O)=CC=C2N1C1=CC=CC=C1 QUERHUCQADQNIP-UHFFFAOYSA-N 0.000 description 1
- SYXXHGIHNILJGS-UHFFFAOYSA-N 4-[(1-cyclohexyl-3-oxo-2-pyridin-2-ylindazol-5-yl)amino]-4-oxobutanoic acid Chemical compound C=1C=CC=NC=1N1C(=O)C2=CC(NC(=O)CCC(=O)O)=CC=C2N1C1CCCCC1 SYXXHGIHNILJGS-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- DYOMCDXGKIGWPH-UHFFFAOYSA-N 5-bromo-1-cyclohexyl-2-phenylpyrazolo[3,4-b]pyridin-3-one Chemical compound C=1C=CC=CC=1N1C(=O)C2=CC(Br)=CN=C2N1C1CCCCC1 DYOMCDXGKIGWPH-UHFFFAOYSA-N 0.000 description 1
- SABNAIAKUAJPSQ-UHFFFAOYSA-N 6-bromo-1-cyclohexyl-2-phenylindazol-3-one Chemical compound C=1C(Br)=CC=C(C(N2C=3C=CC=CC=3)=O)C=1N2C1CCCCC1 SABNAIAKUAJPSQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001118702 Border disease virus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- DXKIQLJPMIMXAO-DEOSSOPVSA-N COC(C[C@H](Cc1c[nH]c2c1cccc2)NC(c(cc1)cc(C2=O)c1N(C1CCCCC1)N2c1ccccc1)=O)=O Chemical compound COC(C[C@H](Cc1c[nH]c2c1cccc2)NC(c(cc1)cc(C2=O)c1N(C1CCCCC1)N2c1ccccc1)=O)=O DXKIQLJPMIMXAO-DEOSSOPVSA-N 0.000 description 1
- WTFYBGAITMAZFV-UHFFFAOYSA-N COC(c1ccccc1NC(Nc(cc1C2O)ccc1N(C1CCCCC1)N2c1ncccc1)=O)=O Chemical compound COC(c1ccccc1NC(Nc(cc1C2O)ccc1N(C1CCCCC1)N2c1ncccc1)=O)=O WTFYBGAITMAZFV-UHFFFAOYSA-N 0.000 description 1
- PLIJUUHTCXTHAB-UHFFFAOYSA-N COc(cc1)ccc1N(C(c1c2)=O)N(C3CCCCC3)c1ccc2Br Chemical compound COc(cc1)ccc1N(C(c1c2)=O)N(C3CCCCC3)c1ccc2Br PLIJUUHTCXTHAB-UHFFFAOYSA-N 0.000 description 1
- VODWUSJUFMJLQE-UHFFFAOYSA-N COc(cc1)ccc1N(C(c1c2)=O)N(C3CCCCC3)c1ccc2C#N Chemical compound COc(cc1)ccc1N(C(c1c2)=O)N(C3CCCCC3)c1ccc2C#N VODWUSJUFMJLQE-UHFFFAOYSA-N 0.000 description 1
- IAGTWNYLOPRMNC-UHFFFAOYSA-O COc(cc1)ccc1[SH2+2]CNC(c(cc1)cc(C(Nc2ccccc2)=O)c1[NH2+]C1CCCCC1)=O Chemical compound COc(cc1)ccc1[SH2+2]CNC(c(cc1)cc(C(Nc2ccccc2)=O)c1[NH2+]C1CCCCC1)=O IAGTWNYLOPRMNC-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108700006884 Hepatitis C virus HVR1 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 241000907337 Modoc virus Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000907507 Ntaya virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 241000907520 Rio Bravo virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000120643 Tyuleniy virus Species 0.000 description 1
- 241000907508 Uganda S virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005035 acylthio group Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- CDUUKBXTEOFITR-UHFFFAOYSA-N alpha-methylserine Natural products OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004996 haloaryloxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-DIFDVCDBSA-N isodrin Chemical compound C1[C@@H]2C=C[C@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-DIFDVCDBSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- SLAZYDOHMYDSQP-NDEPHWFRSA-N methyl (2s)-2-[(1-cyclohexyl-3-oxo-2-phenylindazole-5-carbonyl)amino]-3-(1h-indol-3-yl)propanoate Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)C(=O)C(C=C1C(=O)N2C=3C=CC=CC=3)=CC=C1N2C1CCCCC1 SLAZYDOHMYDSQP-NDEPHWFRSA-N 0.000 description 1
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 1
- OJTXNNHRMCEWAM-UHFFFAOYSA-N methyl 2,5-dichloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC(Cl)=NC=C1Cl OJTXNNHRMCEWAM-UHFFFAOYSA-N 0.000 description 1
- BTNFAFIIGQQSCQ-UHFFFAOYSA-N methyl 2-[(1-cyclohexyl-3-oxo-2-pyridin-2-ylindazol-5-yl)carbamoylamino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)NC1=CC=C(N(C2CCCCC2)N(C=2N=CC=CC=2)C2=O)C2=C1 BTNFAFIIGQQSCQ-UHFFFAOYSA-N 0.000 description 1
- ATFKBWNEVZUSKC-UHFFFAOYSA-N methyl 2-isocyanatobenzoate Chemical compound COC(=O)C1=CC=CC=C1N=C=O ATFKBWNEVZUSKC-UHFFFAOYSA-N 0.000 description 1
- PSOQVWORUVHHKE-UHFFFAOYSA-N methyl 5-chloro-2-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC(C)=NC=C1Cl PSOQVWORUVHHKE-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical group COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001593 sorbitan monooleate Chemical class 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001336411 unassigned viruses Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to viral polymerase inhibitors, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV) , processes for their preparation and their use in the treatment of infections.
- HCV hepatitis C virus
- the Flaviviridae is a group of positive single- stranded RNA viruses with a genome size from 9-15 kb.
- the Flaviviridae consists of various genera including: 1. Hepaciviruses : This genus contains only one species, the Hepatitis C virus (HCV) , which is composed of many genotypes and subtypes .
- HCV Hepatitis C virus
- Flaviviruses This genus includes the Dengue virus, Japanese Tick-Borne and the Yellow Fever virus.
- Flaviviruses Apart from these major groups, there are some additional Flaviviruses that are unclassified.
- Pestiviruses This genus includes three serotypes of bovine viral diarrhoea virus, but no known human pathogens .
- HCV Hepatitis C virus
- the present invention relates to compounds which are viral polymerase inhibitors , in particular inhibitors of viral polymerases within the Flaviviridae family such as HCV .
- Y is independently selected from the group consisting of N, NO and CR in which R is selected from the group consisting of H, halogen, SH, S-optionally substituted Ci- 6 alkyl , OH, optionally substituted d- 6 alkoxy , NH 2 , NH- optionally substituted Ci -6 alkyl, N-di-optionally substituted Ci -6 alkyl and NHCOR 1 in which R 1 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 2 - 6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3- 8 cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl;
- Z is selected from the group consisting of 0, S and NR 1 ' in which R 1 ' is selected from the group consisting of H, OH, optionally substituted Ci -6 alkyl, optionally substituted C 2 - 6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; R 1 is selected from the group consisting of optionally substituted C 2-e alkyl, d -6 alkylene optionally substituted C 3-8 cycloalkyl, Ci -6 alkylene optionally substituted aryl, C 1-6 alkylene optionally substituted heterocyclyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; R 2 is -L-R"' in which L is absent or a linker and R"' is selected from the group consisting of optionally substituted C 3-8 cycloalkyl, optional
- R 3 is selected from the group consisting of C 2 - 6 alkyl; substituted Ci -6 alkyl; halo,- CN; optionally substituted aryl; optionally substituted heterocyclyl; NO 2 ; NR 12 R 13 in which R 12 and R 13 are independently selected from the group consisting of H provided that not both are H, optionally substituted Ci- 6 alkyl, S(O) P R 14 in which p is 0 to 2 and R 14 is selected from the group consisting of H, optionally substituted Ci -6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl optionally substituted heterocyclyl and NR 15 R 16 in which R 15 and R 16 are independently selected from the group consisting of H, optionally substituted Ci_ 6 alkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted aryl and optionally substituted heterocycl
- R 4 is selected from the group consisting of amino acid; optionally substituted C 3 - 8 cycloalkyl; optionally substituted aryl; optionally substituted heterocyclyl; OR 7 in which R 7 is selected from the group consisting of H, optionally substituted Ci- 6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl and optionally substituted heterocyclyl; and NR 5 R 6 ; in which R 5 and R 6 are independently selected from the group consisting of H; optionally substituted Ci -6 alkyl; optionally substituted C 2-6 alkenyl; optionally substituted C 2-6 alkynyl; optionally substituted (CH 2 ) m optionally substituted aryl; optionally substituted (CH 2 ) m optionally substituted heterocyclyl in which m is 0 to 4; S(O) P R 8 in which p is as defined above
- the compounds of formula I are inhibitors of hepatitis C.
- the compounds of formula I inhibit RNA synthesis by the RNA dependent RNA polymerase of HCV (the NS5B protein encoded by HCV) .
- NS5B inhibitors have been clinically validated as potential antiviral agents for the treatment of HCV infection.
- a HCV polymerase inhibitor such as a NS5B inhibitor comprising the compound of formula I defined above.
- an antiviral agent comprising the compound formula I defined above.
- the compound of formula I may be administered in the form of a pharmaceutical composition together with a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising the compound of formula I defined above and a pharmaceutically acceptable carrier.
- the pharmaceutical composition additionally comprises a therapeutically effective amount of one or more antiviral agents such as at least one other anti-HCV agent.
- a method for the treatment of a Flaviviridae viral infection such as a HCV infection which comprises administering an effective amount of the compound of formula I defined above to a subject in need thereof.
- a method of inhibiting the RNA-dependent RNA polymerase activity of the enzyme NS5B, encoded by HCV comprising exposing the enzyme NS5B to an effective amount of the compound of formula I defined above under conditions where the RNA-dependent RNA polymerase activity of the enzyme NS5B is inhibited.
- a method of inhibiting HCV replication comprising exposing a cell infected with HCV to an effective amount of the compound of formula I defined above under conditions where replication of HCV is inhibited.
- the present invention relates to compounds of formula I which inhibit viral polymerases and are useful in the treatment of Flaviviridae viral infections such as hepatitis C.
- the present invention relates to compounds of formula I, salts, solvates, derivatives, prodrugs, tautomers and/or isomers thereof as defined above.
- each Y is CH or one or two of Y is N and the others are CH and n is 1 to 4, more preferably n is 1.
- compounds of formula I have the formula Ia
- R 1 , R 2 and R 3 are as defined above; Y 1 is CH; Y 2 is CH; and Y 3 and Y 4 are independently selected from the group consisting of N and CH.
- R 1 is preferably optionally substituted C 3-8 cycloalkyl such as cyclohexyl, optionally substituted aryl such as phenyl or optionally substituted heterocyclyl .
- L is absent optionally substituted Ci- 6 alkylene or optionally substituted Ci -6 acyl in R 2 .
- R 3 is preferably located at any one or more of positions 4, 5 or 6, preferably the 5 position.
- R 3 is selected from the group consisting of C 2-6 alkyl; substituted Ci -6 alkyl; CN; optionally substituted aryl; optionally substituted heterocyclyl; NR 12 R 13 in which R 12 and R 13 are independently selected from the group consisting of H provided that not both are H, optionally substituted Ci -6 alkyl, S(O) P R 14 in which p is 0 to 2 and R 14 is selected from the group consisting of H, C 2- 6 alkyl, substituted Ci- S alkyl, optionally substituted C 2- 6 alkenyl, optionally substituted C 2 _ 6 a-lkynyl, optionally substituted C 3-8 cycloalkyl, optionally substituted aryl optionally substituted heterocyclyl and NR 15 R 16 in which R 15 and R 16 are independently selected from the group consisting of H, optionally substituted Ci -6 alkyl, optionally substituted C 3 - 6 cycoalkyl, optionally substituted aryl and optionally
- R 4 is selected from the group consisting of amino acid; optionally substituted C 3 - 8 cycloalkyl; optionally substituted aryl; optionally substituted heterocyclyl; OR 7 in which R 7 is selected from the group consisting of C 2 - 6 alkyl, substituted Ci -6 alkyl, optionally substituted C 2 - 6 alkenyl, optionally substituted C 2 .
- R 5 and R 6 are independently selected from the group consisting of H; optionally substituted Ci_ 6 alkyl; optionally substituted C 2-6 alkenyl; optionally substituted C 2 - 6 alkynyl; optionally substituted (CH 2 ) ra optionally substituted aryl; optionally substituted (CH 2 ) m optionally substituted heterocyclyl in which m is 0 to 4; S(O) P R 8 in which p is as defined above and R 8 is selected from the group consisting of H, optionally substituted C !
- R 15 and R 16 are as defined above;
- CR 17 R 18 COR 19 in which R 17 and R 18 are independently selected from the group consisting of H and optionally substituted C 1-6 alkyl or R 17 and R 18 together with the C to which they are attached form an optionally substituted 3 to 6-membered ring and R 19 is selected from the group consisting of 0R 15 in which R 15 is as defined above and NR 20 R 21 in which R 20 and R 21 are selected from the group consisting of H, optionally substituted d- 6 alkyl, optionally substituted aryl and optionally substituted heterocyclyl; and CR 22 (CO 2 R 23 ) CH 2 R 24 in which R 22 and R 23 are independently selected from the group consist
- R 5 and R 6 together with the N to which they are attached form an optionally substituted 5 or 6-membered ring.
- R 3 is optionally substituted heterocyclyl, it is preferably a 5 or 6 membered N-containing heterocyclyl such as tetrazolyl .
- R 3 is optionally substituted Ci- 6 alkyl, halo, CN, NO 2 or optionally substituted heterocyclyl.
- R 2 may be in which
- A is selected from the group consisting of C 3 - 8 cycloalkyl, aryl and heterocyclyl; and R 8 is selected from the group consisting of hydrogen, halo, cyano, nitro, amino, optionally substituted Ci -6 alkanoylamino, optionally substituted Ci -6 alkylsulfonyl, optionally substituted Ci -6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, COOR 9 in which R 9 is hydrogen or optionally substituted Ci -6 alkyl, CONH- (CH 2 ) n -R 10 in which R 10 is optionally substituted C 1-6 alkyl, Ci -6 alkoxycarbonyl or Ci -6 alkanoylamino and n is 1 to 6 and OR 11 in which R 11 is hydrogen, optionally substituted Ci -6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl optionally substituted C 3
- A is preferably cyclohexyl, phenyl or a 5 or 6 membered N-containing heterocyclyl such as pyridyl .
- Z is 0.
- R 1 is preferably optionally substituted C 3- scycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or C 2-6 alkyl substituted with optionally substituted C 3 - 8 cylcoalkyl, optionally substituted aryl or optionally substituted heterocyclyl.
- R 8 is OR 11 in which R 11 is C 1- 6 alkyl or benzyl .
- Ic has the formula Ig
- R 1 , R 2 and R 4 are as defined above.
- R 1 is C 5 . 7 cycloalkyl such as cyclohexyl; phenyl; or a 5 or 6 membered N-containing heterocyclyl such as pyridyl and R 2 is C 5-7 cycloalkyl such as cyclohexyl; optionally substituted phenyl; or heterocyclyl containing an N, 0 or S such as pyridyl, furyl or thienyl .
- Subclasses of compounds of this type are as follows: (i) 7 in which R 1 , R 2 and R 7 are as defined above.
- R 1 is cyclohexyl or phenyl
- R 2 is phenyl optionally substituted with Ci- S alkoxy or benzyloxy
- R 7 is H, Ci -6 alkyl such as Ci -4 alkyl for example methyl; optionally substituted aryl such as phenyl optionally substituted with a d- 6 alkyl which is substituted with amino, acyl and/or Ci -6 alkoxy; or N-containing heterocyclyl such as indolyl optionally substituted with a Ci -6 alkyl which is substituted with amino, acyl and/or Ci -6 alkoxy.
- Representative examples are as follows: Table 1
- R 1 , R 2 , R 5 and R 6 are as defined above.
- R 1 is cyclohexyl or phenyl
- R 2 is phenyl
- one of R 5 and R 6 is H and the other is Ci -6 alkyl substituted with optionally substituted phenyl or optionally substituted heterocyclyl, both R 5 and R 6 are H or together with the N to which they are attached form an optionally substituted 5 or 6-membered heterocyclyl.
- the optional substituents on the phenyl are preferably Ci -6 alkyl, halo such as Cl or F, d- S alkoxy, hydroxy, C 2 - 6 alkenyleneacylCi- 6 alkoxy or acylCi_ 6 alkoxy .
- the heterocyclyl is preferably an unsaturated 5 or 6- membered heteromonocyclic group containing 1 or 2 N atoms such as imidazolyl or pyridinyl; unsaturated condensed heterocyclyl containing 1 to 3 N atoms and optionally S and 0 atoms such as benzothiazol-2-yl, 5- (3-oxo-3 , 4- dihydro-2H-benzo [1, 4] oxazin-6-yl) , benzoxazolyl and benzotriazolyl; unsaturated 5 or 6 -membered heteromonocyclic group containing N and S such as thiazolyl; or unsaturated condensed heterocyclic group containing 0 atoms such as 2-oxo-2H-chromen-7-yl .
- the optional substituents on the heterocyclyl are preferably Ci -6 alkyl, Ci- ⁇ alkyleneacylCi-ealkoxy, acylCi- 6 alkoxy, CF 3 , Ci -6 alkyleneCi -6 alkoxy, carboxy or C 1 - 6 alkenyenecarboxy.
- the optionally substituted 5 or 6-membered heterocyclyl is preferably a saturated N-containing 5 or 6-membered heterocyclyl such as pyrrolidinyl .
- R 1 , R 2 , R 6 , R 17 , R 18 and R 19 are as defined above.
- R 1 is cyclohexyl, phenyl or pyridyl
- R 2 is cyclohexyl or phenyl
- R 6 is H
- R 17 and R 18 are both H or Ci. 6 alkyl, one is H and the other is Ci- S alkyl or Ci -6 alkyl substituted with optionally substituted phenyl or optionally substituted heterocyclyl or together with the C to which they are attached form a 4-membered ring
- R 19 is OR 15 in which R 15 is as defined above or NR 20 R 21 in which one of R 20 and R 21 is H and the other is optionally substituted phenyl or optionally substituted heterocyclyl.
- the optionally substituent on the phenyl or heterocyclyl is preferably hydroxy, acylCi -6 alkoxy, C 2- 6 alkenyleneacyl Ci -6 alkoxy, d- 6 alkylenecarboxy, C 1 - 6 alkylenecarboxy, carboxy or Ci- ⁇ alkylacylCi-ealkoxy.
- the heterocyclyl is preferably an unsaturated condensed heterocyclyl containing 1 to 3 N atoms such as indolyl or quinolinyl.
- R 1 , R 2 , R 6 , p and R 8 are as defined above.
- R 1 is cyclohexyl or phenyl;
- R 2 is optionally substituted phenyl;
- R 6 is H;
- p is 2 and
- R 8 is optionally substituted C 3 - 8 cycloalkyl, optionally substituted phenyl, optionally substituted heterocyclyl, Ci -6 alkyl, d- 6 alkyl substituted with optionally substituted phenyl, C 2-6 alkenyl substituted with optionally substituted phenyl or NR 15 R 16 in which R 15 and R 16 are as defined above.
- the optional substituents on the phenyl or heterocyclyl are preferably Ci- 6 alkoxy, halo such as Cl, Br or F, acylCi -6 alkoxy, nitro, carboxy, amidoC 1-6 alkyl or CF 3 .
- the C 3-8 cycloalkyl is preferably C 3 cycloalkyl.
- the heterocyclyl is preferably an unsaturated 5- membered heteromonocyclic group containing 1 to 2 S atoms such as thiophenyl ; unsaturated condensed heterocyclyl containing 1 to 3 N atoms and optionally S atoms such as benzothiazol-2-yl,benzo [1,2,5] oxodiazol-4-yl and benzothiazol-2-yl or an unsaturated condensed heterocyclyl containing S atoms such as benzothiophenyl .
- Representative examples are as follows : Table 4
- the compounds are of formula Ih
- both R 1 and R 2 are phenyl and R 9 and R 10 are both H or one is H and the other is SO P R 14 in which p and R 14 are as defined above.
- Subclasses of compound of this type are as follows: (i) in which R 1 , R 2 , p and R 14 are as defined above.
- R 1 and R 2 are phenyl; p is 2; and R 14 is optionally substituted phenyl.
- the substituents on the phenyl are preferably nitro, acylCi -6 alkyl, Ci -6 alkyl or halo such as Cl.
- R 1 , R 2 and R 25 are as defined above.
- R 1 is heterocyclyl such as pyridyl
- R 2 is cyclohexyl
- R 25 is Ci- 6 alkylene substituted with carboxylic acid or phenyl substituted with C 1-6 alkyl, carboxylic acid or methoxy carboxylic acid.
- the compounds are of the formula Ii
- R 1 is phenyl or cyclohexyl
- R 2 is optionally substituted phenyl
- R 3' is C 1-6 alkylene substituted with CO 2 CF 3 , Br, CN, NO 2 or tetrazolyl .
- Representative examples are as follows:
- Ci -6 alkyl refers to straight chain or branched chain hydrocarbon groups having from 1 to 6 carbon atoms. Examples include ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl, tert -butyl, pentyl, neopentyl and hexyl .
- C 2-6 alkenyl refers to straight chain or branched chain hydrocarbon groups having at least one double bond of either E or Z stereochemistry where applicable and 2 to 6 carbon atoms. Examples include vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2- propenyl .
- C 2-6 alkynyl refers to straight chain or branched chain hydrocarbon groups having at least one triple bond and 2 to 6 carbon atoms. Examples include ethynyl, 1- or 2-propynyl, 1-, 2- or 3- butynyl and methyl-2-propynyl.
- C 3-8 cycloalkyl refers to non-aromatic cyclic hydrocarbon groups having from 3 to 8 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloctyl, preferably cyclopentyl or cyclohexyl.
- Ci -6 alkoxy refers to an oxy-containing radical having Ci -6 alkyl as defined above. Examples include methoxy, ethoxy, propoxy, butoxy, tert-butoxy and pentoxy.
- aryl refers to single, polynuclear, conjugated or fused residues of aromatic hydrocarbons. Examples include phenyl, biphenyl, terphenyl, quaterphenyl , naphthyl, tetrahydronaphthyl , anthracenyl, dihydroanthracenyl , benzanthracenyl, dibenxanthracenyl and phenanthrenyl . A preferred aryl is phenyl.
- heterocyclyl refers to saturated or unsaturated, monocyclic or polycyclic hydrocarbon groups containing at least one heteroatom atom selected from the group consisting of nitrogen, sulphur and oxygen.
- Suitable heterocyclyls include N-containing heterocyclic groups, such as, unsaturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as, pyrrolidinyl, imidazolidinyl, piperidino or piperazinyl; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as indolyl, isoindo
- Preferred heterocyclyls are pyridinyl, indolyl, benzoxazolyl, benzotriazolyl, thiazolyl, pyrrolidinyl, quinolinyl, thiophenyl, benzothiophenyl, tetrazolyl, furyl, morpholinyl, piperidinyl and 5-oxo-pyrrolidinyl .
- linker group refers to a linear or branched chain of atoms connecting two distinct molecular subunits.
- Suitable linker groups include optionally substituted Ci -6 acyl, optionally substituted Ci -6 alkylene, optionally substituted C 2-6 alkenylene, optionally substituted C 2 - 6 alkynylene, optionally substituted C 3-8 cycloalkylene, optionally substituted C 3-8 cycloalkenylene, optionally substituted divalent aryl, optionally substituted divalent heterocyclyl, optionally substituted Ci -6 SuIfonamido, optionally substituted Ci -6 amido and optionally substituted Ci -6 acylamino.
- Preferred linker groups for R 2 are optionally substituted Ci -6 alkylene or optionally substituted Ci -6 acyl.
- Preferred linker groups for R 3 are optionally substituted C x-6 alkylene, optionally substituted C 2-6 alkenylene, optionally substituted divalent aryl, optionally substituted divalent heterocyclyl, optionally substituted Ci -6 acyl or optionally substituted C 3 _ 8 cycloalkyl.
- amino acid refers to any of the twenty (20) common amino acids generally accepted in the peptide art. Examples include alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glycine, histidine, 5-hydroxyIysine, 4-hydroxyproline, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ⁇ — aminoadipic acid, ⁇ —amino-n-butyric acid, 3,4- dihydroxyphenylalanine , homoserine, ⁇ —methylserine, ornithine, pipecolic acid and thyroxine.
- halo refers to fluorine, chlorine, bromine or iodine .
- Ci -6 alkanoyl refers to a radical provided by the residue after removal of hydroxyl from an organic acid. Examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and trifluoroacetyl .
- optionally substituted refers to a group that may or may not be further substituted with one or more groups selected from Ci -6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, CF 3 , heterocyclyl, halo, haloCi_ 6 alkyl, haloC 3-6 cycloalkyl, haloC 2-6 alkenyl, - S l -
- Preferred optional substituents are selected from the group consisting of Ci -6 alkyl, CF 3 , C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heterocyclyl, halo, haloaryl, haloheterocycylyl, hydroxy, Ci -4 alkoxy, aryloxy, carboxy, amino, acyl, arylacyl, heterocyclylacyl, acylamino, acyloxy, acylCi -s alkoxy, nitro, arylsulphonyl, cyano and the like.
- salts of the compound of formula I are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable salts.
- pharmaceutically acceptable salts include salts of pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric , sulphuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, trihalomethanesulphonic , toluenesulphonic ,
- Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl , alkenyl , alkynyl or aralkyl moiety.
- the salts may be formed by conventional means, such as by reacting the free base form of the compound with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
- solvates may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
- the derivatives of the compound of formula I are preferably pharmaceutically acceptable.
- pharmaceutically acceptable derivative refers to any pharmaceutically acceptable salt, hydrate, ester, amide, active metabolite, analogue, residue or any other compound which is not biologically or otherwise undesirable and induces the desired pharmacological and/or physiological effect.
- pro-drug refers to functional derivatives of the compound of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs” ed. H. Bundgaard, Elsevier, 1985.
- a prodrug may be a pharmacologically inactive derivative of the active compound that requires transformation within the body in order to release the active compound, and that has improved delivery properties over the active compound.
- the transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
- tautomer refers to compounds of formula I which are capable of existing in a state of equilibrium between two isomeric forms. Such compounds may differ in the bond connecting two atoms or groups and the position of these atoms or groups in the compound.
- the formylation step (a) may be carried out using any suitable known process such as a Vilsmeyer formylation or modified version thereof.
- the cycloaddition step (b) may involve a diene and a dienophile or functionally equivalent groups thereof.
- R 3 can be introduced using any suitable known technique such as aromatic substitution chemistry or by appropriate choice of reagents in the cycloaddition reaction.
- RNA dependent RNA polymerase of HCV RNA dependent RNA polymerase of HCV
- the compounds of formula I act by specific inhibition of NS5B
- the compounds may be tested for the lack of inhibitory activity in an assay measuring the activity of an RNA-dependent RNA polymerase other than HCV polymerase or in a DNA dependent RNA polymerase assay.
- the administration of the compound of the present invention may be any suitable means that results in a concentration of the compound that is effective to yield the desired therapeutic or prophylactic response.
- the compound may be contained in any appropriate amount in any suitable carrier and is generally present in an amount of 1-95% by weight of the total weight of the composition.
- the carrier must be "pharmaceutically acceptable" in the sense of being compatible with other ingredients of the composition and not injurious to the subject.
- the pharmaceutical composition may additionally comprise a therapeutically effective amount of one or more antiviral agents such as ribavirin, an antiviral nucleoside, polymerase inhibitor, protease inhibitor and/or inhibitor of viral entry, assembly or egress.
- the composition may also additionally comprise at least one immunomodulatory agent for example an interferon or interferon derivative and/or an inhibitor of inosine-5 ' -monophosphate dehydrogenase (IMPDH) .
- IMPDH inosine-5 ' -monophosphate dehydrogenase
- the composition may be provided in a dosage form that is suitable for oral, parenteral (including intravenous, intramuscular, subcutaneous and intradermal), rectal, vaginal, nasal, inhalation, topical or ocular administration routes.
- the composition may be in form of tablets, capsules, pills, powders, granulates, suspensions, emulsions, liquids, gels including hydrogels, pastes, ointments, creams, plasters, drenches, delivery devices, suppositories, enemas, injectables, implants, sprays or aerosols.
- the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see , e.g., Remington: The Science and Practice of Pharmacy, (19 th ed.). A. R. Gennaro, 1995, Mack Publishing Company, Easton, PA. and Encyclopedia of Pharmaceutical Technology, eds . J.Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York) .
- compositions may be formulated to release the active compound substantially immediately upon administration or at any predetermined time or time period after administration.
- controlled release formulations include (i) formulations that create a substantially constant concentration of the active compound within the body over an extended period of time; (ii) formulations that after a predetermined lay time create a substantially constant concentration of the active compound within the body over an extended period of time; (iii) formulations that sustain active compound action during a predetermined time period by maintaining a relatively, constant, effective active compound level in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the active compound (sawtooth kinetic pattern) ; (iv) formulations that localise active compound action by, e.g., special placement of a controlled release composition adjacent to or in the diseased tissue or organ; and (v) formulations that target active compound action by using carriers or chemical derivatives to deliver the active compound to a particular target cell type.
- Administration of compounds in the form of a controlled release formulation is especially preferred in cases in which the compound has (i) a narrow therapeutic index (i.e., the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small; in general, the therapeutic index, TI, is defined as the ratio of median lethal dose (LD 50 ) to median effective dose (ED 50 ) ) ; (ii) a narrow absorption window in the gastro-intestinal tract; or (iii) a very short biological half-like so that frequent dosing during a day is required in order to sustain the plasma level at a therapeutic level.
- a narrow therapeutic index i.e., the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small
- the therapeutic index, TI is defined as the ratio of median lethal dose (LD 50 ) to median effective dose (ED 50 ) ) ; (ii) a narrow absorption window in the gastro-intestinal tract; or (i
- controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings.
- the active compound is formulated with appropriate excipients into a pharmaceutical composition, that, upon administration to the subject, releases the active compound in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches and liposomes.
- Formulations for oral use include tablets containing the active compound in a mixture with non-toxic pharmaceutically acceptable excipients.
- excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, mirocrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate or sodium phosphate) ; granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates or alginic acid); binding agents (e. g.
- Other pharmaceutically acceptable excipients can be colourants, flavouring agents, plasticisers, humectants, buffering agents and the like.
- the tablets may be uncoated or they may be coated by known techniques, optionally to delay disintegration and absorption in the gastrointestinal tract and thereby providing a sustained action over a longer period.
- the coating may be adapted to release the active compound in a predetermined pattern (e.g., in order to achieve a controlled release formulation) or it may be adapted not to release the active compound until after passage of the stomach (enteric coating) .
- the coating may be a sugar coating, a film coating (e.g., based on hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols and/or polyvinylpyrrolidone) , or an enteric coating (e.g., based on methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac and/or ethylcellulose) .
- a film coating e.g., based on hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols and/or polyvinylpyrrolidone
- enteric coating e.g
- a time delay material such as, glyceryl monostearate or glyceryl distearate may be employed.
- the solid tablet compositions may include a coating adapted to protect the composition from unwanted chemical changes, (e.g., chemical degradation prior to the release of the active compound) .
- the coating may be applied on the solid dosage form in a similar manner as that described in Encyclopedia of Pharmaceutical Technology, supra.
- Formulations for oral use may also be presented as chewing tablets or as hard gelatin capsules wherein the active compound is mixed with an inert solid diluent ⁇ e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active compound is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
- Powders and granulates may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g, a mixer, a fluid bed apparatus or a spray drying equipment.
- Powders, dispersible powders, or granules suitable for preparation of an aqueous suspension by addition of water are convenient dosage forms for oral administration.
- Formulation as a suspension provides the active compound in a mixture with a dispersing or wetting agent, suspending agent, and one or more preservatives.
- Suitable dispersing or wetting agents are, for example, naturally- occurring phosphatides ⁇ e.g., lecithin or condensation products of ethylene oxide with a fatty acid, a long chain aliphatic alcohol or a partial ester derived from fatty acids) and a hexitol or a hexitol anhydride ⁇ e.g., polyoxyethylene stearate, polyoxyethylene sorbitol monooleate, polyoxyethylene sorbitan monooleate and the like) .
- Suitable suspending agents are, for example, sodium carboxymethylcellulose, methylcellulose, sodium alginate and the like.
- the compound may be administered parenterally by injection, infusion or implantation (intravenous, intramuscular, subcutaneous or the like) in dosage forms, formulations or via suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers.
- injection, infusion or implantation intravenous, intramuscular, subcutaneous or the like
- suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers.
- the formulation and preparation of such compositions is well known to those skilled in the art of pharmaceutical formulation. Specific formulations can be found in Remington: The Science and Practice of Pharmacy, supra .
- compositions for parenteral use may be presented in unit dosage forms (e.g., in single-dose ampoules) or in vials containing several doses and in which a suitable preservative may be added (see below) .
- the composition may be in form of a solution, a suspension, an emulsion, an infusion device or a delivery device for implantation or it may be presented as a dry powder to be reconstituted with water or another suitable vehicle before use.
- the composition may include suitable parenterally acceptable carriers.
- the active compound may be incorporated into microspheres, microcapsules, nanoparticles, liposomes or the like for controlled release.
- the composition may include suspending, solubilizing, stabilizing, pH-adjusting agents and/or dispersing agents.
- the pharmaceutical compositions may be in the form suitable for sterile injection.
- a parenterally acceptable liquid vehicle that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1, 3-butanediol, Ringer's solution and isotonic sodium chloride solution.
- the aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl p-hydroxybenzoate) .
- a dissolution enhancing or solubilising agent can be added or the solvent may include 10- 60% w/w of propylene glycol or the like.
- suitable dosage forms for a composition include suppositories (emulsion or suspension type) and rectal gelatin capsules (solutions or suspensions) .
- the active compound is combined with an appropriate pharmaceutically acceptable suppository base such as cocoa butter, esterified fatty acids, glycerinated gelatin and various water-soluble or dispersible bases like polyethylene glycols and polyoxyethylene sorbitan fatty acid esters.
- an appropriate pharmaceutically acceptable suppository base such as cocoa butter, esterified fatty acids, glycerinated gelatin and various water-soluble or dispersible bases like polyethylene glycols and polyoxyethylene sorbitan fatty acid esters.
- Various additives, enhancers or surfactants may be incorporated.
- compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate .
- the active compound may be administered by any of the methods and formulations employed in the art for administration to the respiratory tract.
- the active compound may be administered in the form of a solution or a suspension or as a dry powder.
- Solutions and suspensions will generally be aqueous, for example prepared from water alone (for example sterile or pyrogen-free water) or water and a physiologically acceptable co-solvent (for example ethanol, propylene glycol or polyethylene glycols such as PEG 400) .
- a physiologically acceptable co-solvent for example ethanol, propylene glycol or polyethylene glycols such as PEG 400
- Such solutions or suspensions may additionally contain other excipients for example preservatives (such as benzalkonium chloride) , solubilising agents/surfactants such as polysorbates (eg. Tween 80, Span 80, benzalkonium chloride) , buffering agents, isotonicity-adjusting agents (for example sodium chloride) , absorption enhancers and viscosity enhancers.
- Suspensions may additionally contain suspending agents (for example microcrystalline cellulose and carboxymethyl cellulose sodium) .
- Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the formulations may be provided in single or multidose form. In the latter case a means of dose metering is desirably provided.
- a dropper or pipette this may be achieved by the subject administering an appropriate, predetermined volume of the solution or suspension.
- a spray this may be achieved for example by means of a metering atomising spray pump.
- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the compound is provided in a pressurised pack with a suitable propellant, such as a chlorofluorocarbon (CFC) , for example dichlorodifluoromethane , trichlorofluoromethane or dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant such as a chlorofluorocarbon (CFC) , for example dichlorodifluoromethane , trichlorofluoromethane or dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol may conveniently also contain a surfactant such as lecithin.
- the dose of active compound may be controlled by provision of a metered valve.
- the active compound may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP) .
- a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP) .
- PVP polyvinylpyrrolidine
- the powder composition may be presented in unit dose form, for example in capsules or cartridges of eg. gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- the active compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the active compound will generally have a small particle size, for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation. When desired, formulations adapted to give sustained release of the active compound may be employed.
- the active compound may be administered by oral inhalation as a free-flow powder via a "Diskhaler” (trade mark of Glaxo Wellcome pic or a meter dose aerosol inhaler.
- a "Diskhaler” trade mark of Glaxo Wellcome pic or a meter dose aerosol inhaler.
- compositions may also be administered topically on the skin for percutaneous absorption in dosage forms or formulations containing conventionally non-toxic pharmaceutical acceptable carriers and excipients including microspheres and liposomes.
- the formulations include creams, ointments, lotions, liniments, gels, hydrogels, solutions, suspensions, sticks, sprays, pastes, plasters and other kinds of transdermal drug delivery systems.
- the pharmaceutically acceptable carriers may include emulsifying agents, antioxidants, buffering agents, preservatives, humectants, penetration enhancers, chelating agents, gel forming agents, ointment bases, perfumes and skin protective agents.
- emulsifying agents are naturally occurring gums (e.g., gum acacia or gum tragacanth) and naturally occurring phosphatides (e.g., soybean lecithin and sorbitan monooleate derivatives) .
- antioxidants are butylated hydroxy anisole (BHA) , ascorbic acid and derivatives thereof, tocopherol and derivatives thereof, butylated hydroxy anisole and cysteine.
- preservatives are parabens, such as methyl or propyl p- hydroxybenzoate and benzalonium chloride .
- humectants are glycerin, propylene glycol, sorbitol and urea.
- Examples of penetration enhancers are propylene glycol, DMSO, triethanolamine, N,N-dimethylacetamide, N, N- dimethylformamide, 2-pyrrolidone and derivatives thereof, tetrahydrofurfuryl alcohol and Azone.RTM.
- Examples of chelating agents are sodium EDTA, citric acid and phosphoric acid.
- Examples of gel forming agents are Carbopol, cellulose derivatives, bentonite, alginates, gelatin and polyvinylpyrrolidone.
- ointment bases are beeswax, paraffin, cetyl palmitate, vegetable oils, sorbitan esters of fatty acids (Span) , polyethylene glycols and condensation products between sorbitan esters of fatty acids and ethylene oxide (e.g., polyoxyethylene sorbitan monooleate (Tween) ) .
- compositions described above for topical administration on the skin may also be used in connection with topical administration onto or close to the part of the body that is to be treated.
- the compositions may be adapted for direct application or for introduction into relevant orifice (s) of the body (e.g., rectal, urethral, vaginal or oral orifices) .
- the composition may be applied by means of special delivery devices such as dressings or alternatively plasters, pads, sponges, strips or other forms of suitable flexible material .
- the active compound may be in the form of a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle.
- Additives for instance buffers, preservatives including bactericidal and fungicidal agents, such as phenyl mercuric acetate or nitrate, benzalkonium chloride, or chlorohexidine and thickening agents such as hypromellose may also be included.
- the active compounds may also be presented for use in the form of veterinary compositions, which may be prepared, for example, by methods that are conventional in the art.
- veterinary compositions include those adapted for: (a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions) ; tablets or boluses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the tongue;
- parenteral administration for example by- subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced in the udder via the teat;
- topical applications e.g. as a cream, ointment or spray applied to the skin;
- the compounds of formula I may be used in the treatment of a Flaviviridae viral infection such as a HCV infection.
- treatment means affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiological effect and include: (a) preventing the infection from occurring in a subject that may be predisposed to the infection, but has not yet been diagnosed as having it; (b) inhibiting the infection, i.e., arresting its development; or (c) relieving or ameliorating the effects of the infection, i.e., cause regression of the effects of the infection.
- the prevention of hepatitis C means, for example, administration of a pharmaceutical agent to a subject found to carry a HCV by a test and the like but without a symptom of infection, or to a subject who shows an improved disease state of hepatitis after a treatment of hepatitis C, but who still carries a HCV and is associated with a risk of recurrence of hepatitis.
- subject refers to any animal having a disease or condition which requires treatment with a pharmaceutically-active agent.
- the subject may be a mammal, preferably a human, or may be a non-human primate or non-primates such as used in animal model testing. While it is particularly contemplated that the compounds are suitable for use in medical treatment of humans, it is also applicable to veterinary treatment, including treatment of companion animals such as dogs and cats, and domestic animals such as horses, ponies, donkeys, mules, llama, alpaca, pigs, cattle and sheep, or zoo animals such as primates, felids, canids, bovids and ungulates .
- viral infection refers to the introduction of a virus into cells or tissues, e.g., hepatitis C virus (HCV) .
- HCV hepatitis C virus
- the introduction of a virus is also associated with replication.
- Viral infection may be determined by measuring virus antibody titer in samples of a biological fluid, such as blood, using, e.g., enzyme immunoassay.
- Other suitable diagnostic methods include molecular based techniques, such as RT-PCR, direct hybrid capture assay, nucleic acid sequence based amplification, and the like.
- a virus may infect an organ, e.g., liver, and cause disease, e.g., hepatitis, cirrhosis, chronic liver disease and hepatocellular carcinoma.
- Flaviviridae virus refers to a virus of the family Flaviviridae, which family includes the
- Hepacivirus Flavivirus and Pestivirus or hepatitis C- like virus genera A representative species of the genus of hepatitis C-like viruses is hepatitis C virus.
- Flavivirus include yellow fever virus, tick-borne encephalitis virus, Rio Bravo virus, Japanese encephalitis virus, Tyuleniy virus, Ntaya virus, Kenya S virus, Dengue virus and Modoc virus.
- Representative species of the genus Pestivirus include bovine diarrhea virus, border disease virus and hog cholera virus. Unassigned viruses in the family
- Flaviviridae are included in the meaning of Flaviviridae virus . Dosages
- terapéuticaally effective amount means an amount of the compound of formula I effective to yield a desired therapeutic response.
- Dosage levels of the compound of formula I are of the order of about 0.5 mg to about 20 mg per kilogram body weight, with a preferred dosage range between about 0.5 mg to about 10 mg per kilogram body weight per day (from about 0.5 gms to about 3 gms per patient per day) .
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the subject treated and the particular mode of administration.
- a formulation intended for oral administration to humans may contain about 5 mg to Ig of an active compound with an appropriate and convenient amount of carrier material which may vary from about 5 to 95 percent of the total composition.
- Dosage unit forms will generally contain between from about 5 mg to 500 mg of active ingredient.
- the compounds are administered in a divided dose schedule, such that there are at least two administrations in total in the schedule. Administrations are given preferably at least every two hours for up to four hours or longer; for example the compound may be administered every hour or every half hour.
- the divided-dose regimen comprises a second administration of the compound after an interval from the first administration sufficiently long that the level of active compound in the blood has decreased to approximately from 5-30% of the maximum plasma level reached after the first administration, so as to maintain an effective content of active compound in the blood.
- one or more subsequent administrations may be given at a corresponding interval from each preceding administration, preferably when the plasma level has decreased to approximately from 10-50% of the immediately- preceding maximum.
- the specific dose level for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, active compound combination and the severity of the particular infection undergoing therapy.
- BINAP 2,2' -bis (diphenylphosphino) -1,1' -binaphthyl
- DIPEA diisopropylethylamine
- HATU O- (7-azabenzotriazol-l-yl) -N,N,N' ,N'- tetramethyluronium hexafluorophosphate
- HBTU O-benzotriazol-l-yl-N, N, N' , N' -tetramethyluronium hexafluorophosphate
- HMBC heteronuclear multiple bond correlation
- TFFH fluoro-N, N,N' , N' -tetramethylformamidinium hexafluorophosphate
- the resulting hydrazone is reduced by treatment with approximately 1.2 equivalents of sodium cyanoborohydride .
- the crude N 1 N' -disubstituted hydrazine is then condensed with at least one equivalent of ethyl acetoacetate by heating under dehydrating conditions to yield a pyrazolone derivative.
- the pyrazolone is formylated by treatment with POCl 3 and DMF.
- a solution of the resulting aldehyde and approximately 1.1 equivalents of LDA is then treated with an excess of methyl acrylate or other suitable Diels-Alder substrate.
- the product thus obtained is then dehydrated with pyridinium tosylate and aromatised using DDQ.
- the ester may be hydrolysed by treatment with an aqueous base .
- Phenylhydrazine (4.0 mL, 40.7 mmol) was treated with cyclohexanone (4.2 mL, 40.7 mmol, 1 eq) then dissolved in ethanol (20 mL) and stirred for 10 min at ambient temperature to give hydrazone 1-1.
- Sodium cyanoborohydride (3.1 g, 40.8mmol, 1.2 eq) was added and the mixture was stirred. After 30 minutes LCMS showed complete reduction to the hydrazine 1-2.
- Ethyl acetoacetate (5.2 mL, 40.7mmol, 1 eq) was added and the stirred mixture was heated to reflux under Dean-Stark conditions.
- More ethyl acetoacetate (5.2 mL, 40.7 mmol, 1 eq) was added and heating was continued overnight. The next morning, more ethyl acetoacetate (2 mL, 16.3 mmol, 0.4 eq) was added, along with molecular sieves (-1OmL) . After heating for a further 2 h, more ethyl acetoacetate (3 mL, 24.4 mmol, 0.6 eq) was added, along with more molecular sieves (-1OmL) .
- the Diels-Alder adduct was treated with pyridinium tosylate (530 mg, 2.11mmol, 1.2 eq) in toluene (30 mL) at 90 0 C for 30 min. The mixture was diluted with water, extracted with CH2C12, dried (MgSO4), filtered and concentrated to give dehydrated adduct 1-6.
- the dehydrated adduct was treated with DDQ (480 mg, 2.11mmol, 1.2 eq) in dioxane (50 mL) at reflux (-110 0 C) for 3 h. The mixture was cooled and allowed to stand overnight. It was then diluted with CH2C12 and concentrated to dryness. The residue was diluted with CH2C12 and purified by flash chromatography to yield the target indazolinone 103 as an off-white solid (106 mg, 0.302mmol, 17% for three steps).
- Step 1 HATU (1.25 eq) was added to 2-amino-5- bromobenzoic acid (5 g) , 4-benzyloxyaniline hydrochloride (2 eq) and DIPEA (about 10 eq) in CH 2 Cl 2 (about 200 mL) and the solution allowed to stand for 16 h. The mixture was concentrated and chromatographed on silica to yield amide 2-2.
- Step 2 Pd 2 (dba) 3 (30 mg) and BINAP (30 mg) were added to toluene (10 mL) and the mixture stirred for 10 min. Bromobenzene (200 ⁇ L) , KO 12 Bu (60 mg) and amine 2-2 (100 mg) were added and the mixture heated to reflux for 2 h. The mixture was filtered through Celite, concentrated and chromatographed on silica to yield compound 2-3 as a yellow powder (40 mg, 32%)
- Step 3 PIFA (60 mg) was added to a solution of amide 2- 3 (30 mg) in TFA (5 drops) and CH 2 Cl 2 (5 mL) . Progress was monitored by TLC and when the reaction was complete the mixture was concentrated and chromatographed on silica to yield indazolinone 809 as a yellow gum (18 mg, 60%) .
- Example 2 may be used to prepare other compounds of Formula I by replacing bromobenzene with an appropriate reagent of the formula R 3 ⁇ -Br, or by replacing 4-benzyloxyaniline with an appropriate reagent of the formula R 2 -NH 2 , where R 1 and R 2 are defined herein.
- Step 1 2-Chloro-5-nitrobenzoic acid (1.5 g) was dissolved in cyclohexylamine (4 mL) with stirring and warming. The bright yellow solution was heated in a microwave reactor at 120 0 C for 6 minutes. The resulting gel was diluted with CH 2 Cl 2 (-100 mL) and extracted with 0.2M NaOH (4 x -100 mL) . The aqueous extracts were acidified with 5M HCl, causing precipitation of a white solid. The solid was recovered by filtration and dried. The solid was recrystallised from methanol/water to yield light yellow crystals of amine 3-1 (0.6 g, 31%) .
- Step 2 2-Cyclohexylamino-5-nitrobenzoic acid (3-1) (0.6 g) was dissolved in CH 2 Cl 2 (12 mL) and TEA (2 mL) and treated with BOP (1 g) . After stirring for 2 minutes at room temperature, 2-aminopyridine (0.5 g) was added. The mixture was stirred for 64 h, then another portion of BOP (1 g) was added. After an additional 30 minutes, LCMS indicated almost complete reaction.
- Step 3 Compound 3-2(270 mg) was dissolved in acetonitrile and treated with PIFA (341 mg, 1 eq) at room temperature. After 2h, TFA (1 mL) and additional PIFA (1 eq) were added. After 3h, more PIFA (leq) was added and the mixture was stirred at room temperature for 64 h.
- Example 3 may be used to prepare other compounds of Formula I by replacing cyclohexylamine with an appropriate reagent of the formula R 3 ⁇ -NH 2 , or by replacing 2-aminopyridine with an appropriate reagent of the formula R 2 -NH 2 , where R 1 and R 2 are defined herein.
- Step 1 Amine 2-2 was prepared as described in Example 2.
- Step 2 Amine 2-2 (9.3 g) was treated with an excess of cyclohexanone in acetic acid at reflux for 1 h. The mixture was diluted with EtOAc, washed with aqueous NaOH, dried and concentrated to yield imine 4-1 (10.1 g) .
- Step 3 Imine 4-1 (10.1 g) was treated with sodium borohydride ( ⁇ 5 eq) in EtOH and the reaction heated at reflux for 3 h. Concentration and silica chromatography yielded the target amine 4-2 (8.2 g) .
- Step 4 Amide 4-2 was converted to indazolinone 811 using the analogous procedure to that described in Step 3 of Example 2.
- Step 1 To a stirred solution of 2-amino-4-bromobenzoic acid (1 g) in acetic acid (20 mL) was added cyclohexanone (1.2 eq) and the mixture was stirred at room temperature for Ih. Sodium borohydride (3 eq) was added in portions over 2 h at 40 0 C and the reaction mixture was stirred for an additional 2 h. Concentration gave an oil, which was diluted with water. The precipitated solids were isolated by filtration and purified by chromatography to yield the target 5-1 (1.2 g, 86%) .
- Step 2 Compound 5-2 was prepared from acid 5-1 by the procedure in Step 1 of Example 2, using aniline in place of 4-benzyloxyaniline hydrochloride.
- Step 3 Amide 5-2 was converted to indazolinone 817 using the analogous procedure to that described in Step 3 of Example 2.
- Step 1 2, 5-Dichloropyridine was added to a THF solution of n-BuLi and PMDTA and stirred for 2 hours at -78 0 C before quenching with dry ice. The product was isolated by acid-base work-up in 47% yield.
- Step 2 To a methanolic solution of 2, 5-dichloro- isonicotinic acid was added H 2 SO 4 (cone) (0.5 mL) and the solution was heated to reflux for 12 h. The mixture was cooled to room temperature, neutralized with aqueous NaHCO 3 , extracted into EtOAc and evaporated to afford the methyl ester (6-2) in 89% yield.
- Step 3 To a THF solution of methyl 2, 5-dichloro- isonicotinate was added Fe(acac) 3 (0.05 eq) and NMP (-10 vol) . After cooling to O 0 C, CH 3 MgBr (1.2 eq) was added and the mixture was stirred at 0 0 C for 1 h.
- Step 4 Methyl 5-chloro-2-methylisonicotinate was suspended in a solution of THF/MeOH/water (1:1:1) and to that LiOH (3 eq) was added. The mixture was stirred for 1 h and the resultant carboxylic acid was isolated by aqueous workup .
- Step 5 To a CH 2 Cl 2 solution of acid 6-4 (0.8 g) was added EDC (1.3 eq) and aniline (2 eq) at room temperature. After 10 minutes, the reaction was diluted with CH 2 Cl 2 and washed with dilute HCl. The organic layer was dried and concentrated to yield amide 6-5 (0.9 g, 80%) .
- Step 6 Amide 6-5 was taken up in DME and to this was added NaO'Bu (1.4 eq) , Pd(OAc) 2 (0.05 eq) , CyPF( 11 Bu) (0.05 eq) and aniline (1.2 eq) . The mixture was heated at 100 0 C in a sealed tube for 12 hours and the product was purified by column chromatography.
- Step 7 Amide 6-6 was converted to indazolinone 819 using the analogous procedure to that described in Step 3 of Example 2 but using MeCN as the solvent instead of CH 2 Cl 2 .
- Step 1 Compound 7-1 was prepared from 2-amino-5- methylbenzoic acid using the analogous procedure set out in Step 1 of Example 2, using p-anisidine in place of 4- benzyloxyaniline hydrochloride.
- Step 2 Imine 7-2 was prepared from amine 7-1 by the analogous procedure set out in Step 2 of Example 4.
- Step 3 Imine 7-2 was reduced to amine 7-3 by the analogous procedure set out in Step 3 of Example 4.
- Step 4 Amide 7-3 was converted to an indazolinone using the analogous procedure to that described in Step 3 of Example 2 but in the current example, the substrate was observed to have simultaneously undergone both ring- closure and partial benzylic oxidation to yield trifluoroacetoxy derivative 816.
- Step 1 2-Hydroxynicotinic acid (100 g) was converted to 5-bromo-2-hydroxynicotinic acid (8-1) in 79% yield using the procedure reported in Letavic, M.A. et al., Bioorganic and Medicinal Chemistry Letters, 17, 2007, 2566-2569.
- Step 2 A stirred suspension of 5-bromo-2-hydroxy- nicotinic acid (8-1) (67 g) in POCl 3 (1 vol) was heated to 100 0 C for 14 h. The reaction mixture was cooled to room temperature and quenched by stirring with ice-water for 10 min. The product was extracted into CH 2 Cl 2 and treated with aniline for 1 h. After washing with water, concentration of the organic layer gave crude amide 8-2.
- Step 3 A solution of 8-2 (10 g) in cyclohexylamine (10 eq) was heated to 100 0 C for 14 h, after which time TLC indicated complete conversion of the starting material. The mixture was diluted with dilute HCl solution and the product extracted into CH 2 Cl 2 . The organic extracts were concentrated and recrystallised from diethyl ether to give amine 8-3 (6.5 g, 54%).
- Step 4 Amide 8-3 was converted to indazolinone 807 using the analogous procedure to that described in Step 3 of Example 2.
- ESI-MS m/z calc . for [M+H] + : 374 (Br isotope); found: 374.0
- Bromide 811 was converted to nitrile 812 using the procedure described for Example 9, except that DMF was used as the solvent instead of NMP and the mixture was heated only to 140 0 C.
- Bromide 817 was converted to nitrile 818 using the procedure described for Example 9.
- Bromide 804 was converted to nitrile 810 using the procedure described for Example 9, except that DMF was used as the solvent instead of NMP and the mixture was heated only to 140 0 C.
- Nitro-indazolinone 814 (90 mg) was dissolved in ethanol (30 mL) , treated with 10%Pd/C (5 mg) and placed under an atmosphere of hydrogen. The mixture was stirred vigourously for 16 h before filtering through celite. The filtrate was concentrated to dryness and the residue purified by silica chromatography (eluting with EtOAc/hexanes) to yield amine 815 (70 mg)
- Nitrile 818 (2.6 g) was added to a solution of sulfuric acid and water (1:1) and the reaction mixture was heated to 100 0 C for 1 h. The mixture was diluted with water and the product extracted into chloroform. The organic extracts were concentrated and purified by silica chromatography to yield acid 111 (l.Og, 35%) .
- Nitrile 820 was converted to acid 112 using the procedure described for Example 15.
- Nitrile 812 (130 mg) was treated with acetic acid (0.5 mL and concentrated HCl (3 mL) and stirred at reflux for 50 h. After cooling, the mixture was diluted with water and the product extracted into CH 2 Cl 2 . The organic layer was concentrated and the residue purified by silica chromatography to yield acid 110 (48 mg, 54%) .
- Nitrile 810 was converted to the title tetrazole using trimethylaluminium and trimethylsilylazide according to the analogous procedure reported in B. E. Huff and M. A. Staszak, Tetrahedron Letters, 34, 8011 (1993).
- Indazolinone 816 (40 mg) and NaOH (100 mg) were dissolved in acetone/water (3:1, 4 mL) and heated to reflux. Portions of KMnO 4 were added whenever the purple colouration subsided. After 3 h, TLC indicated that the benzylic oxidation was complete. The mixture was filtered through celite, rinsing the filter with 5M NaOH and acetone . The acetone was removed in vacuo and the resulting aqueous solution was washed with CH 2 Cl 2 . The aqueous layer was then acidified with cone. HCl and extracted with CH 2 Cl 2 , which was dried and concentrated to give acid 107 as a pale tan powder (18 mg, 53%) . ESI-MS m/z calculated for [M+H] + : 367; found: 367.1
- a solution of an appropriate indazolinone- carboxylic acid in an inert solvent is treated with the desired sulfonamide (at least 1 equivalent) , an activating agent such as EDC (about 1 to 2 eq) and, if required, DMAP ( ⁇ 2 eq) , such as in the manner reported by Stansfield et al. in Bioorg Med Chem Lett 17(18), 2007, 5143.
- an activating agent such as EDC (about 1 to 2 eq)
- DMAP ⁇ 2 eq
- DIPEA non-nucleophilic base
- sulfonamides may be purchased or prepared from their corresponding sulfonyl chlorides using techniques that are well known to those skilled in the art. It will also be apparent to one skilled in the art that the general procedure of Examples 20 and 21 may be used to prepare other compounds of Formula I by replacing 2-chlorobenzenesulfonamide (Example 21) or 4 -methoxybenzenesulfonamide (Example 20) with alternative nucleophiles of the formula R 6 -NHS(O) P R 8 , where R 6 , R 8 and p are defined herein.
- certain amides of formula I may be prepared from an appropriate carboxylic acid as set out in the scheme above.
- the indazolinone-carboxylic acid and approximately 1.2 equivalents of an activating agent such as HBTU are dissolved in an appropriate solvent.
- a suitable non-nucleophilic base is added together with the desired amine and the solution is allowed to stand at room temperature until condensation has occurred.
- the products may be isolated by chromatography.
- carboxylic acid 104 (40.5 mg, 0.12 mmol) and HBTU (55 mg, 0.14 mmol, 1.2 eq) were dissolved in DMF (400 ⁇ L) .
- DIPEA 105 ⁇ L, 0.6 mmol, 5 eq
- L-tryptophan methyl ester hydrochloride 37 mg, 0.14 mmol, 1.2 eq
- the solution was allowed to stand at room temperature. After 20 min the reaction mixture was diluted with CH2C12 (2 mL) and washed with water (3 x 1 mL) . The organic layer was filtered through cotton wool and concentrated.
- the crude residue was purified by flash chromatography using ethyl acetate :hexanes (1:1) as eluent to yield the target amide 303 as a white solid (60 mg, 0.11 mmol, 93%) .
- a suitable carboxylic acid substrate is dissolved in H 2 SO 4 , treated with sodium azide and heated to approximately 70° C until the reaction is complete. The reaction mixture is then poured onto an aqueous solution of NaOH and extracted with a suitable organic solvent.
- the amine substrate is dissolved in a suitable solvent such as THF, CH 2 Cl 2 or pyridine and treated with an excess of a suitable electrophile, such as a carboxylic acid halide, an anhydride, a sulfonyl halide or an isocyanate.
- a suitable electrophile such as a carboxylic acid halide, an anhydride, a sulfonyl halide or an isocyanate.
- a non-nucleophilic base such as TEA may be added and the mixture may be heated.
- the volatile components are evaporated and the residue may be purified by chromatography.
- a stirred solution of the indazolinone (5 mg) in pyridine (100 ⁇ l) was treated with benzenesulfonyl chloride (5 ⁇ l) .
- reaction mixture was then heated at 60 0 C for 18 h, cooled to room temperature and the volatiles removed in vacuo. The residue was filtered through a plug of silica gel, eluting with EtOAc. The material was purified further by preparative HPLC to yield the title compound (708) .
- Example 28 (Method T) l-Cyclohexyl-3-oxo-2-phenyl-2 , 3-dihydro-lH-indazole-5- carboxylic acid (Compound 104, Table 1)
- Indazolinone 103 (68 mg, 0.194mmol) was dissolved in a mixture of methanol (5 mL) and 1 M aqueous NaOH (2 mL) and warmed to 60 0 C for 1 h. The mixture was evaporated to dryness and the residue partitioned between 1 M HCl (aq) and CH2C12. The organic layer was filtered through cotton wool and concentrated to yield carboxylic acid 104 as a light brown solid (64 mg, 0.190mmol, 98%).
- the phenol 110 was dissolved in acetone and treated with benzyl bromide (2 eq) and K 2 CO 3 (excess) . After 1 h at room temperature, LCMS indicated complete conversion to the desired ether. The mixture was concentrated, resuspended in dichloromethane and washed with water. The organic phase was dried (MgSO 4 ) and concentrated to yield the target phenol, 114.
- Indazolinone 804 (50 mg) was dissolved in 1-butanol (0.5 tnL) , treated with DIPEA (3 eq) , Pd(OAc) 2 (0.2 eq) and Xantphos (0.2 eq) and placed under an atmosphere of carbon monoxide. The mixture was stirred and heated to 100 0 C for 3 days. After liquid-liquid work-up, the major product was purified by flash chromatography to yield the title ester (108) as a colourless, waxy solid.
- HCV polymerase reactions were carried out using a modified method of Howe et al . , Antimicrobial Agents and Chemotherapy 2004 48(12): 4813-4821. Reactions contained 50 nM NS5Bb ⁇ 21, 20 mM Tris-HCl pH 7.5 , 5 mM MgC12, 3 mM DTT, 25 mM KCl, 0.05% BSA, 0.5% DMSO, 0.4U/ ⁇ L RNasin, and 20 nM Poly r(C) (Amersham) . GTP was present at Km concentration including 0.04 ⁇ Ci/ ⁇ L 33P-GTP, with a total reaction volume of 50 ⁇ L.
- Ava5 cells Human cells containing a genotype Ib subgenomic HCV replicon, Blight et al . , Science 2000 290: 1972-1974 were used in these studies. Cultures were maintained in a sub-confluent state in DMEM with glutamine, non-essential amino acids, 10% heat-inactivated foetal bovine serum and G418.
- HCV RNA analysis was seeded at a concentration of 2000 cells per well into 96 well tissue culture trays and grown overnight in the presence of G418. The following day the cell monolayers were exposed to dilutions of compound. Stock solutions (5OmM) of each compound were made in DMSO and diluted in culture media lacking G418 on the day of addition. Compounds were tested in a final concentration range of 20-100 uM downwards. Cells were treated for three consecutive days with the test compounds. Medium was replaced daily with fresh test compounds. Analysis of HCV RNA was performed 24 h following the last addition of test compound.
- HCV replicon RNA was assayed by real-time reverse transcription (RT-PCR) using primers located in the HCV NS5B gene and quantified on the basis of HCV RNA standards and relative amounts of cellular actin mRNA.
- Example 36 Cytotoxicity of compounds against Ava5 cells was assessed using the MTT assay (Watanabe et al . , Journal of Virological Methods 1994 48:257-265). Plates were prepared as described for the HCV Replicon assay, and cytotoxicity analysis was performed 24 h following the last addition of test compound. Culture media in each test well was replaced with lmg/mL MTT solution, and the cells incubated at 37°C for several hours. The MTT solution was then replaced with isopropanol, and cytotoxicity assessed by reading the plates at 540/690 nm and determining colour development in each test well.
- HCV polymerase reactions were carried out using a modified method of Howe et al., Antimicrobial Agents and Chemotherapy 2004 48(12): 4813-4821. Reactions contained 25 nM NS5b ⁇ 21, 20 mM Tris-HCl pH 7.5 , 5 mM MgCl 2 , 3 mM DTT, 0.05% BSA, 0.4U/ ⁇ L RNasin, and 5 nM RNA (500 nt template) . All NTPs used were at Km concentrations, and 0.04 ⁇ Ci/ ⁇ L 33 P-UTP, with a total reaction volume of 50 ⁇ L.
- the in vivo efficacy of the compounds may be evaluated using known methods such as those described in: Lanford, R. E. "The chimpanzee model of hepatitis C virus. Framing the Knowledge of Viral Hepatitis", 197-218 IHL Press, 2006,- Lanford, R. E., Bigger, C, Bassett, S., Klimpel, G. , "The chimpanzee model of hepatitis C virus infections", Institute for Laboratory Animal Research
- a model that employs a surrogate virus — in particular GB virus B — may be used according to known methods such as described in Haqshenas, G. et al., "A chimeric GB virus B encoding the hepatitis C virus hypervariable region 1 is infectious in vivo” , Journal of General Virology 88, 2007, 895 and Bright, H. et al . , "Development of a GB Virus B Marmoset Model and Its Validation with a Novel Series of Hepatitis C Virus NS3 Protease Inhibitors", Journal of Virology, 78(4), 2004, 2062.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des inhibiteurs des polymérases virales, et en particulier sur de telles polymérases de la famille des Flaviviridae dont le virus de l'hépatite C (VHC), sur leur préparation, et sur leur utilisation dans le traitement d'infections.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007902702 | 2007-05-21 | ||
AU2007902702A AU2007902702A0 (en) | 2007-05-21 | Viral polymerase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008141385A1 true WO2008141385A1 (fr) | 2008-11-27 |
Family
ID=40031323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2008/000714 WO2008141385A1 (fr) | 2007-05-21 | 2008-05-21 | Inhibiteurs de polymérases virales |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008141385A1 (fr) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014038A1 (fr) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | Dérivés de 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide utilisés comme inhibiteurs de la parp-1 |
WO2013036994A1 (fr) * | 2011-09-16 | 2013-03-21 | Biota Scientific Management Pty Ltd | Composés pour le traitement des infections par vhc |
WO2013152391A1 (fr) * | 2012-04-11 | 2013-10-17 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérase virale |
CN103483274A (zh) * | 2013-09-25 | 2014-01-01 | 江苏快达农化股份有限公司 | 一种制备苄嘧磺隆的方法 |
JP2014528412A (ja) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | 抗ウイルス化合物 |
US9782408B2 (en) | 2014-10-06 | 2017-10-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US9856253B2 (en) | 2015-04-17 | 2018-01-02 | Abbvie, Inc. | Tricyclic modulators of TNF signaling |
US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
US10160748B2 (en) | 2015-04-17 | 2018-12-25 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10793547B2 (en) | 2016-12-09 | 2020-10-06 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11179367B2 (en) | 2018-02-05 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for treating cystic fibrosis |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US11786528B2 (en) | 2018-06-04 | 2023-10-17 | Exscientia Ltd. | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
EP4345102A1 (fr) * | 2022-09-30 | 2024-04-03 | Medizinische Universität Innsbruck | Synthèse améliorée d'otviciclib |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448777A (en) * | 1981-08-20 | 1984-05-15 | Kali-Chemie Pharma Gmbh | 1-Phenylindazole-3-one compounds, process and intermediates for their preparation, and pharmaceutical compositions containing same |
EP0580402A2 (fr) * | 1992-07-20 | 1994-01-26 | E.R. Squibb & Sons, Inc. | Aminediols comme inhibiteurs de protéase |
US6180637B1 (en) * | 1998-05-11 | 2001-01-30 | Arzneimittelwerk Dresden Gmbh | 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments |
WO2004093872A1 (fr) * | 2003-03-31 | 2004-11-04 | Eli Lilly And Company | Utilisation de derives amides d'acide 3-oxo-1,3-dihydro-indazole-2-carboxylique comme inhibiteurs de la phospholipase |
US20070254892A1 (en) * | 2006-04-27 | 2007-11-01 | Takeshi Sagara | Dihydropyrazolopyrimidinone derivatives |
-
2008
- 2008-05-21 WO PCT/AU2008/000714 patent/WO2008141385A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448777A (en) * | 1981-08-20 | 1984-05-15 | Kali-Chemie Pharma Gmbh | 1-Phenylindazole-3-one compounds, process and intermediates for their preparation, and pharmaceutical compositions containing same |
EP0580402A2 (fr) * | 1992-07-20 | 1994-01-26 | E.R. Squibb & Sons, Inc. | Aminediols comme inhibiteurs de protéase |
US6180637B1 (en) * | 1998-05-11 | 2001-01-30 | Arzneimittelwerk Dresden Gmbh | 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments |
WO2004093872A1 (fr) * | 2003-03-31 | 2004-11-04 | Eli Lilly And Company | Utilisation de derives amides d'acide 3-oxo-1,3-dihydro-indazole-2-carboxylique comme inhibiteurs de la phospholipase |
US20070254892A1 (en) * | 2006-04-27 | 2007-11-01 | Takeshi Sagara | Dihydropyrazolopyrimidinone derivatives |
Non-Patent Citations (4)
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014038A1 (fr) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | Dérivés de 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide utilisés comme inhibiteurs de la parp-1 |
JP2014521620A (ja) * | 2011-07-26 | 2014-08-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Parp−1阻害剤としての3−オキソ−2,3−ジヒドロ−1h−インダゾール−4−カルボキサミド誘導体 |
US9073893B2 (en) | 2011-07-26 | 2015-07-07 | Nerviano Medical Sciences S.R.L. | 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors |
WO2013036994A1 (fr) * | 2011-09-16 | 2013-03-21 | Biota Scientific Management Pty Ltd | Composés pour le traitement des infections par vhc |
JP2014528412A (ja) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | 抗ウイルス化合物 |
WO2013152391A1 (fr) * | 2012-04-11 | 2013-10-17 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérase virale |
US9447080B2 (en) | 2012-04-11 | 2016-09-20 | Biota Scientific Management Pty Ltd. | Viral polymerase inhibitors |
CN103483274A (zh) * | 2013-09-25 | 2014-01-01 | 江苏快达农化股份有限公司 | 一种制备苄嘧磺隆的方法 |
US10258624B2 (en) | 2014-10-06 | 2019-04-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10758534B2 (en) | 2014-10-06 | 2020-09-01 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US11426407B2 (en) | 2014-10-06 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US12168009B2 (en) | 2014-10-06 | 2024-12-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US9782408B2 (en) | 2014-10-06 | 2017-10-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
US10160748B2 (en) | 2015-04-17 | 2018-12-25 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
US10266532B2 (en) | 2015-04-17 | 2019-04-23 | Abbvie Inc. | Tricyclic modulators of TNF signaling |
US10273238B2 (en) | 2015-04-17 | 2019-04-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
US9856253B2 (en) | 2015-04-17 | 2018-01-02 | Abbvie, Inc. | Tricyclic modulators of TNF signaling |
US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11186566B2 (en) | 2016-09-30 | 2021-11-30 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US10793547B2 (en) | 2016-12-09 | 2020-10-06 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11453655B2 (en) | 2016-12-09 | 2022-09-27 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US11155533B2 (en) | 2017-10-19 | 2021-10-26 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
US11179367B2 (en) | 2018-02-05 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for treating cystic fibrosis |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US11786528B2 (en) | 2018-06-04 | 2023-10-17 | Exscientia Ltd. | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
EP4345102A1 (fr) * | 2022-09-30 | 2024-04-03 | Medizinische Universität Innsbruck | Synthèse améliorée d'otviciclib |
WO2024068853A1 (fr) * | 2022-09-30 | 2024-04-04 | Medizinische Universität Innsbruck | Synthèse améliorée d'otviciclib |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008141385A1 (fr) | Inhibiteurs de polymérases virales | |
JP4970048B2 (ja) | イミダゾ[4,5−c]ピリジン化合物および抗ウイルス治療の方法 | |
KR101389165B1 (ko) | 이치환된 프탈라진 헤지호그 (hedgehog) 경로 길항제 | |
WO2011153588A1 (fr) | Inhibiteurs de polymérase virale | |
CN1795195B (zh) | 新颖的吡啶并吡嗪及其作为激酶调节剂的用途 | |
RU2330851C2 (ru) | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА | |
SK4322003A3 (en) | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | |
ES2795748T3 (es) | Derivados de 2-amino-bencimidazol como inhibidores de 5-lipoxigenasa y/o prostaglandina E sintasa para tratar enfermedades inflamatorias | |
KR20060005333A (ko) | 특정의 신규한 이미다조피리딘 및 그의 용도 | |
JP2010537998A (ja) | イミダゾピリジン類似体、およびWnt−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用 | |
AU2005263135A1 (en) | Viral polymerase inhibitors | |
ES2525756T3 (es) | Imidazo [1,2-a] piridinas como moduladores de JNK | |
CN107106561A (zh) | 用于治疗疾病的硫酸乙酰肝素生物合成抑制剂 | |
TW201542567A (zh) | 用於增進先天性免疫反應之化合物及方法 | |
BRPI0707689A2 (pt) | inibidores de polimerase viral | |
CN103957908A (zh) | 作为包括肝细胞癌在内的癌症的抑制剂和作为肝炎病毒复制抑制剂的取代的氨基噻唑 | |
WO2023042879A1 (fr) | Dérivé hétérocyclique bicyclique ayant une activité inhibitrice de la croissance virale et composition pharmaceutique le contenant | |
WO2012174312A2 (fr) | Dérivés de benzimidazole en tant qu'agents antiviraux | |
CN110914253A (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
JP5826856B2 (ja) | ウイルスポリメラーゼ阻害剤 | |
WO2003106446A1 (fr) | Agents anti-gnrh non peptidiques, compositions pharmaceutiques et procedes d'utilisation | |
WO2004096774A1 (fr) | Derives d'acyle isoindoline et d'acyle isoquinoline utilises comme agents antiviraux | |
CN113748113A (zh) | 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物 | |
CN116253740A (zh) | 环状双苄基异喹啉类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08747982 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08747982 Country of ref document: EP Kind code of ref document: A1 |